Literature DB >> 7558132

CD40-activated human naive surface IgD+ B cells produce IgG2 in response to activated T-cell supernatant.

C Servet-Delprat1, J M Bridon, D Blanchard, J Banchereau, F Brière.   

Abstract

Human IgG2 is an isotype associated with immune responses to carbohydrates. While interleukin-10 (IL-10) induced CD40-activated naive surface (s)IgD+ human B cells to secrete IgG1 and IgG3, none of 20 recombinant cytokines tested alone, or in combination with IL-10, was able to induce these cells to produce IgG2. This was not due to a specific inability of these sIgD+ B cells, as they could be induced to secrete microgram amounts of IgG2, as well as the three other IgG subclasses, when cultured with an anti-CD3-activated CD4+ T-cell clone. The supernatant of this activated CD4+ T-cell clone contained a soluble factor(s) able to induce the secretion of IgG2 by CD40-activated sIgD+ B cells. Following activation, blood T cells also produced a factor(s) inducing CD40-activated naive B cells to secrete IgG2. This CD4+ T-cell clone will thus permit us ultimately to define the presently uncharacterized cytokine(s) inducing naive B cells to secrete IgG2. This will provide a new insight for the study of immunodeficiencies involving a selective defect in IgG2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558132      PMCID: PMC1383917     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  Ligation of CD40 induces sterile transcripts of multiple Ig H chain isotypes in human B cells.

Authors:  M D Jumper; J B Splawski; P E Lipsky; K Meek
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

2.  Frequency of human B cells that differentiate in response to anti-CD3-activated T cells.

Authors:  K Amoroso; P E Lipsky
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

3.  Interleukin 4 induces synthesis of IgE and IgG4 in human B cells.

Authors:  M Lundgren; U Persson; P Larsson; C Magnusson; C I Smith; L Hammarström; E Severinson
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

4.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.

Authors:  J G Gilles; J Arnout; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

5.  Role of CD40 antigen and interleukin-2 in T cell-dependent human B lymphocyte growth.

Authors:  D Blanchard; C Gaillard; P Hermann; J Banchereau
Journal:  Eur J Immunol       Date:  1994-02       Impact factor: 5.532

6.  Human IgM+IgD+ B cells, the major B cell subset in the peripheral blood, express V kappa genes with no or little somatic mutation throughout life.

Authors:  U Klein; R Küppers; K Rajewsky
Journal:  Eur J Immunol       Date:  1993-12       Impact factor: 5.532

7.  Regulation of C gamma subclass germ-line transcripts in human peripheral blood B cells.

Authors:  A Kitani; W Strober
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

Review 8.  The CD40 antigen and its ligand.

Authors:  J Banchereau; F Bazan; D Blanchard; F Brière; J P Galizzi; C van Kooten; Y J Liu; F Rousset; S Saeland
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

9.  Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.

Authors:  C Caux; C Massacrier; B Vanbervliet; C Barthelemy; Y J Liu; J Banchereau
Journal:  Int Immunol       Date:  1994-08       Impact factor: 4.823

10.  Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3.

Authors:  F Brière; C Servet-Delprat; J M Bridon; J M Saint-Remy; J Banchereau
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  1 in total

1.  Synergistic augmentative effect of interleukin-10 and CD27/CD70 interactions on B-cell immunoglobulin synthesis.

Authors:  H Nagumo; K Agematsu
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.